Adding Molnupiravir Or Nirmatrelvir-Ritonavir To Usual Care Not Linked To Improvements In Clinical Outcomes In Patients Hospitalized With COVID-19 Pneumonia, Study Finds

Infectious Disease Advisor (7/18, Basilio) reported, “The addition of molnupiravir or nirmatrelvir-ritonavir to usual care was not associated with improvements in clinical outcomes in patients hospitalized with COVID-19 pneumonia, according to findings.” Researchers said, “Current evidence does not support the addition of molnupiravir or nirmatrelvir-ritonavir to usual care, which could include other antivirals, for adults hospitalized with COVID-19.” The findings were published in The Lancet Infectious Diseases.